Pitt Shield

First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound.

Authors: Abrahao A, Meng Y, Llinas M, Huang Y, Hamani C, Mainprize T, Aubert I, Heyn C, Black SE, Hynynen K, Lipsman N, Zinman L

MR-guided focused ultrasound (MRgFUS) is an emerging technology that can accurately and transiently permeabilize the blood-brain barrier (BBB) for targeted drug delivery to the central nervous system. We conducted a single-arm, first-in-human trial to investigate the safety and feasibility of MRgFUS-induced BBB opening in eloquent primary motor cortex in four volunteers with amyotrophic lateral sclerosis (ALS). Here, we show successful BBB opening using MRgFUS as demonstrated by gadolinium leakage at the target site immediately after sonication in all subjects, which normalized 24 hours later. The procedure was well-tolerated with no serious clinical, radiologic or electroencephalographic adverse events. This study demonstrates that non-invasive BBB permeabilization over the motor cortex using MRgFUS is safe, feasible, and reversible in ALS subjects. In future, MRgFUS can be coupled with promising therapeutics providing a targeted delivery platform in ALS.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To assess the safety and feasibility of transiently opening the blood–brain barrier in the primary motor cortex of ALS patients using MR-guided focused ultrasound.
Disease model ALS
MRI or image guidance method MR-guided focused ultrasound (ExAblate Neuro 4000 integrated with 3T MRI) using task-based functional MRI mapping of hand/foot motor cortex for target localization, fitted with a Cosman-Roberts-Wells stereotactic frame for stereotactic accuracy, planning MRI registered to baseline CT, and real-time MR thermometry and acoustic (cavitation) monitoring during sonication.
Targeted brain region(s) M1
Target coordinates Not provided
Route of administration intravenous

Outcomes and Safety

Summary of Outcomes 220 kHz MRgFUS transiently and reversibly opened the BBB in the M1 of ALS patients.
Duration of biological effect 24 h
Safety-related matter Safe and well-tolerated; only mild transient AEs like headache reported.

Brain Region

Ultrasound Parameters

Ultrasound instrument ExAblate Neuro 4000
FUS Frequency 220 kHz
FUS Intensity not reported
FUS Pressure not reported
FUS Mode pulsed
Pulse duration 2.64 ms
Duration of a single FUS session 6 min
Focal Characteristics 7 mm
Treatment frequency single session

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search